Genetic Technologies Limited (GTG.AX)
| Previous close | 0.0030 |
| Open | 0.0020 |
| Bid | 0.0020 x 10000000 |
| Ask | 0.0030 x 249000000 |
| Day's range | 0.0020 - 0.0020 |
| 52-week range | 0.0020 - 0.0080 |
| Volume | |
| Avg. volume | 2,832,563 |
| Market cap | 27.7M |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0000 |
| Earnings date | 26 Feb 2024 - 01 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Here's Why Shareholders May Want To Be Cautious With Increasing Genetic Technologies Limited's (ASX:GTG) CEO Pay Packet
Key Insights Genetic Technologies to hold its Annual General Meeting on 21st of November Total pay for CEO Simon...
GlobeNewswireGene Business Update: Private Hospital Partnership; Expanded Multi-Test for Australian Market and Commercial Partner for Cancer Clinical Trial
MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, ”Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, is pleased to provide an update on the company activities for the quarter ending 30 September 2023. Highlights: Partnership signed with the Gold Coast Private Hospital (a member of Healthscope), to establish a Precision Medicine Clinic at the hospital.GeneType Multi-Test
- GlobeNewswire
GeneType Predicting Risk of Pancreatic Cancer: Major Breakthrough in Early Detection and Treatment
MELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of a peer-reviewed research paper validating geneType’s Pancreatic Cancer risk assessment test. Highlights: Pancreatic cancer has a very high mortality rate, approximately 76%1 of those diagnosed will die within 1 year. The five-year survival rate is
